FDA Clears Roche CMV Test for Marketing | GenomeWeb

NEW YORK (GenomeWeb News) – Roche today announced that the US Food and Drug Administration has given premarket approval for the firm's molecular test to assess a patient's viral load of cytomegalovirus.

The fully automated Cobas AmpliPrep/Cobas TaqMan CMV Test is the first FDA-approved laboratory test for quantifying CMV DNA in human plasma specimens, Roche said. The PCR-based test is designed to run on the Cobas AmpliPrep/Cobas TaqMan System and can be combined with the Cobas p 630 instrument, which provides an integrated pre-analytical primary tube handling solution.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.